ViiV Healthcare (GSK) said that phase 1 data on third-generation integrase strand transfer inhibitor VH184 indicates that it could be dosed as infrequently as twice a year.
Long-acting formulations of VH1843 were given either subcutaneously or intramuscularly. One of the formulations demonstrated steady drug levels through month 7.
A separate in vitro study found that VH1843 had an enhanced resistance profile compared to Gilead Sciences’ (GILD) bictegravir.
ViiV also released 12-month interim data from a phase 2b trial examining a combination of lotivibart every four months with monthly Apretude (cabotegravir). Results showed that 94% of individuals receiving lotivibart intravenously maintained viral suppression, and 82% of those who received the treatment subcutaneously compared to 88% in the standard-of-care cohort.
ViiV is majority owned by GSK (GSK), with Pfizer (PFE) and Shionogi (SGIOY)(SGIOF).
